Home » Archive

News

Marketwire, News, Syndication »

Quidel to Hold Fourth Quarter and Full Year 2011 Financial Results Conference Call on February 29, 2012

Posted by Mary Canady February 2nd, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Feb 2, 2012) – Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions and cellular-based virology assays, will release fourth quarter and full year 2011 financial results after market…

More...

Marketwire, News, Syndication »

Quidel to Hold Fourth Quarter and Full Year 2011 Financial Results Conference Call on February 29, 2012

Posted by Mary Canady February 2nd, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Feb 2, 2012) – Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions and cellular-based virology assays, will release fourth quarter and full year 2011 financial results after market…

More...

News, Syndication, Xconomy »

San Diego Life Sciences Strengthened in Recession, Outpacing Nation

Posted by sandiegobiotech February 1st, 2012 .
No Comments

Employment in San Diego’s life sciences sector grew by 15 percent over the past two years, as biopharmas, medical device companies, and other employers added roughly 5,550 jobs here—raising…

[[Click headline to continue reading.]]

More...

Marketwire, News, Syndication »

Ardea Biosciences Prices Public Offering of Common Stock

Posted by Mary Canady February 1st, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Feb 1, 2012) – Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced the pricing of an underwritten public offering of 8,500,000 shares of its common stock, offered at a price to the public of $17.00 per share. The gros…

More...

News, Syndication, Xconomy »

Vertex’s Big Day Felt Like Moon Landing, Seattle Researcher Says

Posted by sandiegobiotech February 1st, 2012 .
No Comments

Bonnie Ramsey said three years ago that a cystic fibrosis drug from Vertex Pharmaceuticals was a huge medical advance in the making, and would end up being an achievement on par with putting a man on…

[[Click headline to continue reading.]]

More...

Marketwire, News, Syndication »

Ardea Biosciences Announces Proposed Public Offering of Common Stock

Posted by Mary Canady January 31st, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Jan 31, 2012) – Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be…

More...

News, Syndication, Xconomy »

Vertex Gets FDA Go-Ahead To Sell New Cystic Fibrosis Drug

Posted by sandiegobiotech January 31st, 2012 .
No Comments

[Updated: 1:25 pm] Vertex Pharmaceuticals is now officially more than just a one-hit wonder. The Cambridge, MA-based biotech company (NASDAQ: VRTX), best known for its hepatitis C drug, has won…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

Optimer, Following Pfizer’s Playbook, Has Big Plans for Antibiotic

Posted by sandiegobiotech January 31st, 2012 .
No Comments

Pfizer was where Pedro Lichtinger learned about pharmaceutical marketing from people who did some amazing things. For starters, New York-based Pfizer (NYSE: PFE) turned an old-school antifungal…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

Four Themes to Watch in Personalized Medicine

Posted by sandiegobiotech January 30th, 2012 .
No Comments

Good morning from Mountain View, CA, and from the close of the 2012 Personalized Medicine World Conference, which brought together thought leaders of business, government, healthcare-delivery,…

[[Click headline to continue reading.]]

More...

Marketwire, News, Syndication »

Medistem and ERCell Initiate Phase II RECOVER-ERC Heart Failure Trial

Posted by Mary Canady January 30th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Jan 30, 2012) – Medistem Inc. (PINKSHEETS: MEDS) together with its Russian Licensee, ERCell LLC, announced successful dosing of 3 heart failure patients in the Non-Revascularizable IschEmic Cardiomyopathy treated with Re…

More...